… exposure targets in ganciclovir therapy remains and to observe underexposure linked with
failure of therapy requires analysis of a wider patient population. Still, ganciclovir remains a …

… Oral ganciclovir monotherapy is as efficacious as sequential … oral ganciclovir therapy in liver
transplant recipients. Pre-emptive treatment was equally as effective as long term ganciclovir …

… ganciclovir therapy, with the best response seen in the transplant recipients. Viremia ceased
in 14 (93.3%) of 15 patients after a mean of 4.7 days of therapy; viruria ceased in eight (53.3…

… nature of early ganciclovir treatment in preventing … therapy (9% of all patients with low grade
antigenaemia subsequently developed CMV disease) and the discontinuation of ganciclovir …

… outcomes in transplant patients treated with oral valganciclovir or intravenous ganciclovir for
… use of oral valganciclovir for treatment of CMV disease in SOT recipients. Clinicians should, …

… ganciclovir resistance mutation during treatment … Treatment with oral valganciclovir or
intravenous ganciclovir results in similar and low rates of resistance mutations in SOT recipients. …

… ganciclovir is a valuable treatment for cytomegalovirus infection in patients with AIDS and in
organ transplant recipients… observed when ganciclovir therapy is deferred in patients whose …

… have included mostly renal or heart transplant recipients and few liver transplant recipients.
… trial of long-term ganciclovir prophylaxis in our liver transplant recipients. Ganciclovir …

… to a single course of antiCMV therapy (intravenous ganciclovir in five, foscarnet sodium and
… ganciclovir treatment and improved without specific antiCMV therapy). None of these seven …

… Ganciclovir, an acyclic nucleoside analog, has been shown to have activity against CMV in
the treatment of … , ganciclovir was given to marrow transplant recipients excreting CMV after …